

Notice of Shareholder Update Webinar

20 August 2025 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, advises that it will host a shareholder webinar at 1:00pm AEST (11:00am AWST) on Tuesday, 26 August 2025.

During the webinar, CEO and Managing Director, Dr. Michael Thurn and other members of the executive team will provide an update on the following:

- Topline results from the 12-month Open Label Extension (OLE) Study using NUZ-001 for the treatment of amyotrophic lateral sclerosis (ALS)
- Ongoing efforts to expedite the FDA’s review of the Clinical Hold Complete Response for NUZ-001’s Investigational New Drug (IND) application
- Continued preclinical initiatives
- Outlook on the Company’s near-term objectives

The briefing will be followed by a Q&A session. Questions can be submitted now to enquiries@neurizon.com, during online registration, or in written form during the webinar. Anyone wishing to attend the webinar must register via the following:

- **Registration:** <https://bit.ly/26082025>
- **Date and time:** 1:00pm AEST (11:00am AWST) on Tuesday, 26 August 2025

For those who cannot attend the webinar, a recording will be made available via the Company’s website.

-ENDS-

This announcement has been authorized for release on behalf of the Neurizon Board by Dr. Michael Thurn, Managing Director and Chief Executive Officer.

For further information, please contact:

Dr. Michael Thurn
Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
enquiries@neurizon.com
+61 (3) 9692 7222

Lidija Damjanovic
Head of Marketing and Corporate Affairs
Neurizon Therapeutics Limited
lidija@neurizon.com
+61 (0) 425 700 504

Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited